Imaging noradrenergic influence on amyloid pathology in mouse models of Alzheimer’s disease

[1]  Mathias Hoehn,et al.  Locus Ceruleus Degeneration Promotes Alzheimer Pathogenesis in Amyloid Precursor Protein 23 Transgenic Mice , 2006, The Journal of Neuroscience.

[2]  S. DeKosky,et al.  Binding of the Positron Emission Tomography Tracer Pittsburgh Compound-B Reflects the Amount of Amyloid-β in Alzheimer's Disease Brain But Not in Transgenic Mouse Brain , 2005, The Journal of Neuroscience.

[3]  Michael V. Green,et al.  PET imaging of brain with the β-amyloid probe, [11C]6-OH-BTA-1, in a transgenic mouse model of Alzheimer’s disease , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  D. Selkoe,et al.  Cell biology of protein misfolding: The examples of Alzheimer's and Parkinson's diseases , 2004, Nature Cell Biology.

[5]  S. DeKosky,et al.  P2-031 Amyloid deposits in transgenic PS1/APP mice do not bind the amyloid pet tracer, PIB, in the same manner as human brain amyloid , 2004, Neurobiology of Aging.

[6]  C. Kahn,et al.  Role for neuronal insulin resistance in neurodegenerative diseases. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[7]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[8]  G. Higgins,et al.  Transgenic mouse models of Alzheimer's disease: phenotype and application , 2003, Behavioural pharmacology.

[9]  K. Någren,et al.  Brain acetylcholinesterase activity in mild cognitive impairment and early Alzheimer’s disease , 2003, Journal of neurology, neurosurgery, and psychiatry.

[10]  B. Hyman,et al.  Imaging Aβ Plaques in Living Transgenic Mice with Multiphoton Microscopy and Methoxy‐X04, a Systemically Administered Congo Red Derivative , 2002, Journal of neuropathology and experimental neurology.

[11]  et al.,et al.  Discrimination between Alzheimer Dementia and Controls by Automated Analysis of Multicenter FDG PET , 2002, NeuroImage.

[12]  M. Iyo,et al.  Positron emission tomography: quantitative measurement of brain acetylcholinesterase activity using radiolabeled substrates. , 2002, Methods.

[13]  Chester A. Mathis,et al.  A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. , 2002, Bioorganic & medicinal chemistry letters.

[14]  G. Small,et al.  Binding Characteristics of Radiofluorinated 6-Dialkylamino-2-Naphthylethylidene Derivatives as Positron Emission Tomography Imaging Probes for β-Amyloid Plaques in Alzheimer's Disease , 2001, The Journal of Neuroscience.

[15]  G. Alexander,et al.  Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome. , 2001, JAMA.

[16]  Brian J. Bacskai,et al.  Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy , 2001, Nature Medicine.

[17]  W. Heiss,et al.  Relevance of Experimental Ischemia in Cats for Stroke Management: A Comparative Reevaluation , 2001, Cerebrovascular Diseases.

[18]  S. Tanada,et al.  Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: A positron emission tomography study , 2000, Annals of neurology.

[19]  D. Dickson,et al.  Amyloid Phenotype Characterization of Transgenic Mice Overexpressing both Mutant Amyloid Precursor Protein and Mutant Presenilin 1 Transgenes , 1999, Neurobiology of Disease.

[20]  B. Sommer,et al.  Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  N. Foster,et al.  Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease , 1997, Annals of neurology.

[22]  Hitoshi Shinotoh,et al.  Measurement of acetylcholinesterase by positron emission tomography in the brains of healthy controls and patients with Alzheimer's disease , 1997, The Lancet.

[23]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[24]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[25]  S. Thibodeau,et al.  Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. , 1996, The New England journal of medicine.

[26]  J. Rommens,et al.  Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene , 1995, Nature.

[27]  G. Schellenberg,et al.  Candidate gene for the chromosome 1 familial Alzheimer's disease locus , 1995, Science.

[28]  D. Pollen,et al.  Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease , 1995, Nature.

[29]  L. Mucke,et al.  Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.

[30]  B. Winblad,et al.  A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid , 1992, Nature Genetics.

[31]  M. Pericak-Vance,et al.  Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.

[32]  H. Wiśniewski,et al.  Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[33]  R. Hilker,et al.  Multitracer PET imaging in Heidenhain variant of Creutzfeldt–Jakob disease , 2005, Journal of Neurology.

[34]  J. Klein,et al.  Multitracer PET imaging in a patient with Heidenhain variant of Creutzfeldt-Jakob disease , 2004 .

[35]  G. Small,et al.  Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[36]  A. Thiel,et al.  Penumbral probability thresholds of cortical flumazenil binding and blood flow predicting tissue outcome in patients with cerebral ischaemia. , 2001, Brain : a journal of neurology.

[37]  K. Wienhard,et al.  In-vivo measurements of regional acetylcholine esterase activity in degenerative dementia: comparison with blood flow and glucose metabolism , 2000, Journal of Neural Transmission.

[38]  J. Hardy,et al.  Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.